Brief: Sio Gene Therapies Announces Granting Of FDA Fast Track Designation
21/10/2021 15:12
Oct 21 (Reuters) - Sio Gene Therapies Inc SIOX.O :
* SIO GENE THERAPIES ANNOUNCES GRANTING OF FDA FAST TRACK
DESIGNATION FOR INVESTIGATIONAL AXO-AAV-GM1 (AAV9-GLB1) GENE
THERAPY IN PATIENTS WITH GM1 GANGLIOSIDOSIS
Source text for Eikon: ID:nGNXbhYph6
Further company coverage: SIOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sio Gene Therapies
See all newsBrief: Sio Gene Therapies Inc - On March 14, Got Notice That Nasdaq Has Determined That Company's Common Stock Will Be Delisted From Nasdaq Capital Market
Brief: Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
Brief: Sio Gene Therapies Inc. Announces Board Approval Of Plan Of Complete Liquidation, Dissolution
Brief: Sio Gene Therapies Announces Second Quarter Financial Results
Brief: Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results